These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 16392231)

  • 1. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade.
    Sharma S; Kashour T; Philipp R
    Tex Heart Inst J; 2005; 32(3):405-10. PubMed ID: 16392231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
    Bonderman D; Nowotny R; Skoro-Sajer N; Jakowitsch J; Adlbrecht C; Klepetko W; Lang IM
    Chest; 2005 Oct; 128(4):2599-603. PubMed ID: 16236930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bosentan: a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases].
    Volkov AV; Iudkina NN; Nikolaeva EV; Kurmukov IA; Glukhova SI; Nasonov EL
    Ter Arkh; 2014; 86(5):32-9. PubMed ID: 25026800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension.
    Hamaguchi Y; Fujimoto M; Hasegawa M; Matsushita T; Takehara K
    J Dermatol Sci; 2009 Jul; 55(1):66-7. PubMed ID: 19342201
    [No Abstract]   [Full Text] [Related]  

  • 11. Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.
    Varga J
    Curr Rheumatol Rep; 2003 Apr; 5(2):145-6. PubMed ID: 12628045
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
    van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
    Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
    Cozzi F; Montisci R; Marotta H; Bobbo F; Durigon N; Ruscazio M; Sfriso P; Iliceto S; Todesco S
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():49-53. PubMed ID: 16919011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?
    Kuntzen C; Gülberg V; Gerbes AL
    Gastroenterology; 2005 Jan; 128(1):164-8. PubMed ID: 15633133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.
    Hachulla E; Coghlan JG
    Ann Rheum Dis; 2004 Sep; 63(9):1009-14. PubMed ID: 15308510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan.
    Foley RJ; Metersky ML
    Respiration; 2008; 75(2):211-4. PubMed ID: 16293957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
    Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosentan for chronic thromboembolic pulmonary hypertension.
    Confalonieri M; Kodric M; Longo C; Vassallo FG
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
    Giannelli G; Iannone F; Marinosci F; Lapadula G; Antonaci S
    Curr Med Res Opin; 2005 Mar; 21(3):327-32. PubMed ID: 15811199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.
    Kotlyar E; Sy R; Keogh AM; Kermeen F; Macdonald PS; Hayward CS; McNeil KD; Celermajer DS
    Cardiol Young; 2006 Jun; 16(3):268-74. PubMed ID: 16725066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.